Home

cent Hôtel intenter laction novartis zolgensma press release Conscient pourquoi pas En colère

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Path clears for Novartis's Zolgensma after FDA lifts longstanding hold
Path clears for Novartis's Zolgensma after FDA lifts longstanding hold

Novartis faces serious delays in registration of Zolgensma in Russia
Novartis faces serious delays in registration of Zolgensma in Russia

Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters
Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters

Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times
Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times

Novartis used faulty data for world's most expensive drug Zolgensma
Novartis used faulty data for world's most expensive drug Zolgensma

Novartis Media Release guide - August 2019
Novartis Media Release guide - August 2019

Novartis Boosts Zolgensma Production Capacity After FDA Clearance
Novartis Boosts Zolgensma Production Capacity After FDA Clearance

Zolgensma Launch “On Track,” but Significant Challenges Remain - Bionest
Zolgensma Launch “On Track,” but Significant Challenges Remain - Bionest

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Four Takeaways from the Zolgensma Pricing Storm
Four Takeaways from the Zolgensma Pricing Storm

News Archive | Novartis
News Archive | Novartis

Novartis releases long-term data for SMA gene therapy
Novartis releases long-term data for SMA gene therapy

Novartis Reveals Two Deaths Related to SMA Drug Zolgensma | BioSpace
Novartis Reveals Two Deaths Related to SMA Drug Zolgensma | BioSpace

AMM européenne pour Scemblix® (asciminib) de Novartis
AMM européenne pour Scemblix® (asciminib) de Novartis

Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR
Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR

Zolgensma gene therapy for sma patients: long-term data
Zolgensma gene therapy for sma patients: long-term data

FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace
FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace

Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA
Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA

$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian
$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge

Novartis allies with Voyager to develop gene therapies in $1.3bn deal
Novartis allies with Voyager to develop gene therapies in $1.3bn deal

Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma

ICNApedia - Zolgensma Benefits Observed in Presymptomatic SMA Patients
ICNApedia - Zolgensma Benefits Observed in Presymptomatic SMA Patients